Quick Takeaways:
- PetVivo announced the publication of a peer-reviewed clinical study in Veterinary Recordevaluating Spryng with OsteoCushion Technology for dogs with stifle osteoarthritis (OA) and suspected cranial cruciate disease (CCD). The prospective proof-of-concept study enrolled 40 client-owned dogs, each receiving a single intra-articular injection, with outcomes assessed over 84 days using clinician evaluations.
- The study found that 55% of dogs achieved at least a 25% improvement in the primary endpoint of modified Glasgow Composite Pain Scale (mGCPS), while improvements were also observed across all clinician and owner-assessed outcome measures. Investigators concluded that Spryng demonstrated feasibility in managing pain associated with CCD and OA, while recommending additional studies using objective outcome measures to further validate its clinical benefits.
- Conducted by a multi-center team of veterinary specialists from leading US referral hospitals, the findings strengthen the growing clinical evidence for PetVivo’s collagen-elastin hydrogel technology and support its broader strategy of expanding veterinarian adoption through scientific validation and continued orthopedic research
Why It Matters?
PetVivo’s new study shows that a single intra-articular Spryng injection with OsteoCushion technology can improve pain and function in dogs with stifle osteoarthritis and suspected cranial cruciate disease.
While the authors call for larger studies with objective metrics, the findings add to the clinical evidence base for PetVivo’s collagen-elastin hydrogel, support its use as a non-surgical, injection-based option for canine orthopedic pain, and help strengthen the company’s strategy to drive veterinarian adoption through published data and ongoing orthopedic research.
Source: Globenewswire
